Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Emergent BioSolutions Inc (NYSE:EBS)

28.12
Delayed Data
As of Jun 30
 -0.05 / -0.18%
Today’s Change
27.01
Today|||52-Week Range
44.38
-29.72%
Year-to-Date
Why Emergent BioSolutions Inc. Procured a Lower Price Today
Jun 22 / MotleyFool.com - Paid Partner Content
Emergent (EBS) BioThrax sBLA Accepted for FDA Review
Jun 20 / Zacks.com - Paid Partner Content
Why is Emergent BioSolutions Inc. (EBS) Down 22% Today?
Jun 22 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close28.17
Today’s open28.22
Day’s range27.96 - 28.70
Volume820,243
Average volume (3 months)622,319
Market cap$1.1B
Dividend yield--
Data as of 06/30/2016

Growth & Valuation

Earnings growth (last year)+60.23%
Earnings growth (this year)-14.18%
Earnings growth (next 5 years)+23.50%
Revenue growth (last year)+16.14%
P/E ratio15.9
Price/Sales3.62
Price/Book1.68

Competitors

 Today’s
change
Today’s
% change
ACORAcorda Therapeutics ...+0.11+0.45%
TBPHTheravance Biopharma...-0.19-0.83%
ACHNAchillion Pharmaceut...-0.04-0.51%
INVAInnoviva Inc-0.10-0.94%
Data as of 06/30/2016

Financials

Next reporting dateAugust 4, 2016
EPS forecast (this quarter)-$0.20
Annual revenue (last year)$522.8M
Annual profit (last year)$62.9M
Net profit margin12.03%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Daniel J. Abdun-Nabi
CFO, Treasurer &
Executive VP-Corporate Services
Robert G. Kramer
Corporate headquarters
Gaithersburg, Maryland

Forecasts

Partner Offers

Search for Jobs